Search research articles
Contact Us
Filters
Showing results (211-220 of 328) with videos related to
Page
of 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program
P McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
P McLaughlin, A J Grillo-López, B K Link, et al.
American Journal of Hematology
|
September 20, 2018
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Priyanka A Pophali, Andrew Ip, Melissa C Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2019
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Yucai Wang, Umar Farooq, Brian K Link, et al.
American Journal of Hematology
|
November 27, 2018
Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma
Nicholas Mackrides, Jennifer Chapman, Melissa C Larson, et al.
Haematologica
|
November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Sean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Leukemia
|
December 31, 2016
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
D Rossille, I Azzaoui, A L Feldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
A K Nooka, C Nabhan, X Zhou, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Blood Cancer Journal
|
August 3, 2018
History of autoimmune conditions and lymphoma prognosis
Geffen Kleinstern, Matthew J Maurer, Mark Liebow, et al.
Page
of 33
Search research articles
Search
Showing results (211-220 of 328) with videos related to
Sort By:
Page
of 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program
P McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
P McLaughlin, A J Grillo-López, B K Link, et al.
American Journal of Hematology
|
September 20, 2018
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Priyanka A Pophali, Andrew Ip, Melissa C Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2019
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Yucai Wang, Umar Farooq, Brian K Link, et al.
American Journal of Hematology
|
November 27, 2018
Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma
Nicholas Mackrides, Jennifer Chapman, Melissa C Larson, et al.
Haematologica
|
November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Sean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Leukemia
|
December 31, 2016
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
D Rossille, I Azzaoui, A L Feldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
A K Nooka, C Nabhan, X Zhou, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Blood Cancer Journal
|
August 3, 2018
History of autoimmune conditions and lymphoma prognosis
Geffen Kleinstern, Matthew J Maurer, Mark Liebow, et al.
Page
of 33